TY - JOUR
T1 - 5-Iodo-2′-Deoxyuridine-Protein Conjugates
T2 - Synthesis and Enzymatic Degradation
AU - Baranowska-Kortylewicz, Janina
AU - Adelstein, S. James
AU - Kassis, Amin I.
PY - 1990
Y1 - 1990
N2 - Several halogenated analogs of thymidine and cytidine possess antineoplastic and antiviral activity. They are also powerful sensitizers of bacterial and mammalian cells to lethal effects of x-irradiation. An important factor limiting the effectiveness of these agents in therapy is their extremely short half-life in circulation due to rapid hepatic dehalogenation. An approach to this problem is to deliver the drug directly to its target using monoclonal antibodies. This study evaluates the lysosomotropic delivery systems of halogenated pyrimidines using 5-iodo-2′-deoxyuridine [IUdR] as a model. IUdR, derivatized and activated at either the 3′- or the 5′-position forms covalent adducts with the ε-amino groups of the lysine residues in proteins (bovine serum albumin [BSA], and immunoglobulins [IgG]). Two methods suitable for conjugation of IUdR to proteins involving either the formation of acyl-imidazoles in the reaction of IUdR succinates with N,N′-carbonyldiimidazole or the preparation of N-succinimidyl esters of IUdR succinates were established. Both derivatives express comparable reactivity toward proteins. The degree of IUdR incorporation is easily controlled by the ratio of reagents. The succinate “arm“ linking IUdR to protein is susceptible to lysosomal hydrolysis in vitro releasing intact IUdR. The half-life of the IUdR-IgG conjugate in the presence of the lysosomal enzymes was shown to be approximately twice that of the IUdR-BSA conjugate.
AB - Several halogenated analogs of thymidine and cytidine possess antineoplastic and antiviral activity. They are also powerful sensitizers of bacterial and mammalian cells to lethal effects of x-irradiation. An important factor limiting the effectiveness of these agents in therapy is their extremely short half-life in circulation due to rapid hepatic dehalogenation. An approach to this problem is to deliver the drug directly to its target using monoclonal antibodies. This study evaluates the lysosomotropic delivery systems of halogenated pyrimidines using 5-iodo-2′-deoxyuridine [IUdR] as a model. IUdR, derivatized and activated at either the 3′- or the 5′-position forms covalent adducts with the ε-amino groups of the lysine residues in proteins (bovine serum albumin [BSA], and immunoglobulins [IgG]). Two methods suitable for conjugation of IUdR to proteins involving either the formation of acyl-imidazoles in the reaction of IUdR succinates with N,N′-carbonyldiimidazole or the preparation of N-succinimidyl esters of IUdR succinates were established. Both derivatives express comparable reactivity toward proteins. The degree of IUdR incorporation is easily controlled by the ratio of reagents. The succinate “arm“ linking IUdR to protein is susceptible to lysosomal hydrolysis in vitro releasing intact IUdR. The half-life of the IUdR-IgG conjugate in the presence of the lysosomal enzymes was shown to be approximately twice that of the IUdR-BSA conjugate.
UR - http://www.scopus.com/inward/record.url?scp=0025268764&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025268764&partnerID=8YFLogxK
U2 - 10.1089/sct.1990.6.1
DO - 10.1089/sct.1990.6.1
M3 - Article
C2 - 2343200
AN - SCOPUS:0025268764
VL - 6
SP - 1
EP - 13
JO - Selective Cancer Therapeutics
JF - Selective Cancer Therapeutics
SN - 1043-0733
IS - 1
ER -